Trump Says Will Reduce Drug Prices By Around 1,500%
US President Donald Trump said on Monday that he will reduce drug prices by 1,400% to 1,500%, while reiterating his promise of slapping higher tariffs on the import of pharmaceuticals.
"Going to do a number on costs of drugs in US," he said during the briefing. This comes nearly a month after Trump, in letters to pharmaceutical majors like Johnson & Johnson and Pfizer, set a deadline of Sept. 29 to lower drug prices.
Trump asked them to extend the "most-favored-nation" pricing to Medicaid. "Provide your full portfolio of existing drugs at MFN rates for every single Medicaid patient," he stated.
Trump noted that a failure to comply with these directives by Sept. 29 would compel his administration to "deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices".
Notably, the big pharma firms which have been issued the letter includes AstraZeneca, Bristol Myers, GSK, Merck, Novartis, Roche and Sanofi.
Earlier this month he also said that the tariffs on pharmaceuticals can go up to 250%. He clarified that initially he will push small tariffs but in over a year it would move to 150% and then it will rise to 250%. This move is in order to move the production of pharmaceuticals in the country.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.